Around 700 employees in research, administration and infrastructure, and about 140 visiting scientists from 40 different countries are employed at the Helmholtz Centre for Infection Research.
Our scientists pursue research to expand our knowledge of the fundamental mechanisms behind medically relevant infectious diseases.
To the open positions
The Friends of the Helmholtz Centre for Infection Research support dedicated young scientists and promote their networking with other researchers and companies. Furthermore, they enable scientific events and publications.
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these bacteria. Scientists of the Helmholtz Centre for Infection Research (HZI) in Braunschweig recently were the first to conduct a so-called transcriptome study of this pathogen within infected lymphatic tissue of mammals, i.e. a simultaneous…
HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver…
Though viruses are troublesome and often even hazardous pathogens, many of them remain well-hidden and cause only mild diseases or none at all. After some modification, these viruses can be utilized to protect the body from other pathogens. Researchers make use of their infectious properties by first eliminating the disease-causing components, then loading the harmless viruses with fragments of…
Bacteria are increasingly developing resistance to the common antibiotics – not least because of the excessive and sometimes incorrect use of these medications. Moreover, antibiotics can have unpleasant side effects as they also kill beneficial bacteria. Dr Gregor Fuhrmann, a pharmacist and scientist at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), aims to develop…
Infections with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) among people who inject drugs (PWID) are a global health problem. For example, sharing of drug preparation equipment within this population contributes to more than 80% of newly acquired HCV infections. As a response to these circumstances, scientists at TWINCORE validated a simple and safe method to reduce…
Helmholtz Centre for Infection ResearchInhoffenstraße 738124 Braunschweig+49 531 email@example.com
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)Universitätscampus E8 166123 Saarbrücken+49 681 firstname.lastname@example.org
TWINCOREZentrum für Experimentelle und Klinische InfektionsforschungFeodor-Lynen-Str. 730625 Hannover+49 511 email@example.com
Study Centre HannoverFeodor-Lynen-Straße 1530625 Hannover+49 511 5350 firstname.lastname@example.org